Terns Pharmaceuticals pulls in $87m Series C

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on treating non-alcoholic steatohepatitis and other chronic liver diseases, has secured $87 million in Series C financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this